Sertolinoma maligno en un canino criptórquido con hiperplasia prostática benigna quística: reporte de caso

The case of an 8-year-old Beagle canine, who was attended at the ASMEVET veterinary hospital in the city of Tunja, Colombia, is presented. The owner reported that in recent months he has been losing hair, has increased water consumption, has not been neutered, and more recently is depressed, lack of appetite and with signs of dysuria. On physical examination, generalized alopecia and gynecomastia were observed, and the prostate was enlarged and asymmetric. Transabdominal ultrasonography revealed an enlarged prostate, with heteroechogenic parenchyma and microcysts, and the testicles were retained at the level of the apex of the bladder. Enrofloxacin was administered for 5 days, and meloxicam for 4 days, and then the patient underwent celiotomy to remove the retained testicles. The histopathological study reported malignant sertolinoma. Fine needle aspiration of prostate tissue revealed cells consistent with benign prostatic hyperplasia. After 90 days of bilateral orchiectomy, remission of alopecia was observed and ultrasound evaluation showed a decrease in the size of the prostate.Se presenta el caso de un canino de 8 años, raza Beagle, que fue atendido en el hospital veterinario ASMEVET de la ciudad de Tunja, Colombia. El propietario informó que en los últimos meses ha estado perdiendo, ha aumentado el consumo de agua, no ha sido castrado, y que recientemente se encuentra deprimido, inapetente y con signos de disuria. Al examen físico se observa alopecia generalizada y ginecomastia, y la próstata se encuentra aumentada de tamaño y asimétrica. La ultrasonografía transabdominal revela próstata aumentada de tamaño, con parénquima heteroecogénico y microquistes, y los testículos se encontraban retenidos a la altura del vértice de la vejiga. Se administró enrofloxacina por 5 días, y meloxicam por 4 días, y luego se sometió a celiotomía para extirpar los testículos retenidos. El estudio histopatológico reportó sertolinoma maligno. La muestra del tejido prostático mediante aspiración con aguja fina reveló células compatibles con hiperplasia prostática benigna. Después de los 90 días de la orquiectomía bilateral se observó la remisión de la alopecia y la ecografía control mostró disminución del tamaño de la próstata

Dengue en el embarazo: efectos en el feto y el recién nacido.

The risk of dengue virus infection during pregnancy has increased due to the current rash of frequent and severe dengue epidemics. The effects of dengue virus in the fetus and newborn children have been studied only superficially and with contradictory results. Therefore, a retrospective cohort study was conducted in Medellin, Colombia, to describe the fetal and postnatal effects of dengue virus infection acquired during pregnancy. Twenty-two babies born from mothers who suffered dengue during the epidemics of 1998 were compared with babies from non-infected mothers. In the exposed cohort, three premature births occurred, three children suffered from fetal anomalies and four children were born with low weight. In the non-exposed children, none of these problems were found. Psychomotor development was normal in both groups. Only the low weight subgroup was statistically significant (Fisher test, p = 0.045). These results suggested that the children from women with dengue during pregnancy present low weight, greater frequency of premature birth and increased fetal distress. A larger sample is necessary to confirm these results.El riesgo de infección por el virus del dengue durante el embarazo se está incrementando ante mayores y más severas epidemias, y las consecuencias sobre el feto y el recién nacido han sido poco estudiadas y, en otros casos, los resultados han sido contradictorios. Por esta razón, se realizó en Medellín un estudio de cohorte retrospectiva, cuyo objetivo fue determinar los efectos que produce el dengue durante el embarazo sobre el feto y el recién nacido. En dicho estudio se evaluaron 22 recién nacidos hijos de mujeres que presentaron dengue durante la epidemia de 1998 y se compararon con 24 recién nacidos, hijos de mujeres embarazadas sin dengue. En la cohorte con dengue se encontraron 3 niños prematuros, 3 niños con sufrimiento fetal y 4 niños con bajo peso al nacer. En la cohorte no expuesta no se encontraron niños con estos problemas. El desarrollo psicomotor fue normal en ambos grupos. De las observaciones anteriores, sólo fue estadísticamente significativa la frecuencia de niños con bajo peso al nacer (prueba exacta de Fisher, p=0,045). Estos resultados preliminares muestran que los recién nacidos de madres que sufrieron dengue durante la gestación tuvieron riesgo de bajo peso al nacer y presentaron con mayor frecuencia prematurez y sufrimiento fetal, aunque se requiere aumentar el tamaño de la muestra para confirmar estos resultados. Sin embargo, es necesario estrechar la vigilancia a las madres embarazadas con dengue dados los efectos nocivos sobre la evolución del recién nacido

What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from theENIGMABipolar Disorder Working Group

MRI‐derived brain measures offer a link between genes, the environment and behavior and have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of BD have been underpowered, leading to varied results and uncertainty regarding effects. The Enhancing Neuro Imaging Genetics through Meta‐Analysis (ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discoveries, generate consensus findings and inform future hypothesis‐driven studies of BD. Through this effort, over 150 researchers from 20 countries and 55 institutions pool data and resources to produce the largest neuroimaging studies of BD ever conducted. The ENIGMA Bipolar Disorder Working Group applies standardized processing and analysis techniques to empower large‐scale meta‐ and mega‐analyses of multimodal brain MRI and improve the replicability of studies relating brain variation to clinical and genetic data. Initial BD Working Group studies reveal widespread patterns of lower cortical thickness, subcortical volume and disrupted white matter integrity associated with BD. Findings also include mapping brain alterations of common medications like lithium, symptom patterns and clinical risk profiles and have provided further insights into the pathophysiological mechanisms of BD. Here we discuss key findings from the BD working group, its ongoing projects and future directions for large‐scale, collaborative studies of mental illness

Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial

Background Tranexamic acid reduces surgical bleeding and decreases mortality in patients with traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and death. We aimed to assess the effects of tranexamic acid in patients with TBI. Methods This randomised, placebo-controlled trial was done in 175 hospitals in 29 countries. Adults with TBI who were within 3 h of injury, had a Glasgow Coma Scale (GCS) score of 12 or lower or any intracranial bleeding on CT scan, and no major extracranial bleeding were eligible. The time window for eligibility was originally 8 h but in 2016 the protocol was changed to limit recruitment to patients within 3 h of injury. This change was made blind to the trial data, in response to external evidence suggesting that delayed treatment is unlikely to be effective. We randomly assigned (1:1) patients to receive tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo. Patients were assigned by selecting a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was head injury-related death in hospital within 28 days of injury in patients treated within 3 h of injury. We prespecified a sensitivity analysis that excluded patients with a GCS score of 3 and those with bilateral unreactive pupils at baseline. All analyses were done by intention to treat. This trial was registered with ISRCTN (ISRCTN15088122), ClinicalTrials.gov (NCT01402882), EudraCT (2011-003669-14), and the Pan African Clinical Trial Registry (PACTR20121000441277). Results Between July 20, 2012, and Jan 31, 2019, we randomly allocated 12 737 patients with TBI to receive tranexamic acid (6406 [50·3%] or placebo [6331 [49·7%], of whom 9202 (72·2%) patients were treated within 3 h of injury. Among patients treated within 3 h of injury, the risk of head injury-related death was 18·5% in the tranexamic acid group versus 19·8% in the placebo group (855 vs 892 events; risk ratio [RR] 0·94 [95% CI 0·86-1·02]). In the prespecified sensitivity analysis that excluded patients with a GCS score of 3 or bilateral unreactive pupils at baseline, the risk of head injury-related death was 12·5% in the tranexamic acid group versus 14·0% in the placebo group (485 vs 525 events; RR 0·89 [95% CI 0·80-1·00]). The risk of head injury-related death reduced with tranexamic acid in patients with mild-to-moderate head injury (RR 0·78 [95% CI 0·64-0·95]) but not in patients with severe head injury (0·99 [95% CI 0·91-1·07]; p value for heterogeneity 0·030). Early treatment was more effective than was later treatment in patients with mild and moderate head injury (p=0·005) but time to treatment had no obvious effect in patients with severe head injury (p=0·73). The risk of vascular occlusive events was similar in the tranexamic acid and placebo groups (RR 0·98 (0·74-1·28). The risk of seizures was also similar between groups (1·09 [95% CI 0·90-1·33]). Interpretation Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 h of injury reduces head injury-related death. Patients should be treated as soon as possible after injury. Funding National Institute for Health Research Health Technology Assessment, JP Moulton Charitable Trust, Department of Health and Social Care, Department for International Development, Global Challenges Research Fund, Medical Research Council, and Wellcome Trust (Joint Global Health Trials scheme)